Atrial Fibrillation, Deep Vein Thrombosis, Mitral Valve Disease
Conditions
Keywords
anticoagulation, stewardship program, anticoagulants, clinical pharmacist, heparin, warfarin
Brief summary
This study aims at evaluating the implementation of clinical-pharmacist-led anticoagulation stewardship program in Egyptian tertiary hospital to promote a culture of safety around anticoagulants.
Detailed description
One of the high-alert medication categories that may cause significant patient harm if not used correctly is anticoagulants. It is not clear if medication errors are more common with this category in specific compared to other medication categories, but the ramifications of a medication error with the use of anticoagulation agents is without a doubt detrimental to the patient's health and more serious than most of other drug categories. This prospective study evaluates the impact of implementing an anticoagulation stewardship program, led by clinical pharmacists, on anticoagulation therapy outcomes during patient hospitalization by the percent of medication errors reduction, percent of adverse drug events reduction, and percent of evidence-based guidelines compliance improvement.
Interventions
OTHERAnticoagulation Stewardship Program
A clinical-pharmacist led anticoagulation stewardship program that includes: 1. Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication. 1c.Warfarin dosage adjustment algorithms. 1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants. 5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients.
Sponsors
Ain Shams University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
Quasi experimental study (separate sample pre-test post-test design)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All hospitalized patients on therapeutic anticoagulant medication during their hospitalization period.
Exclusion criteria
1. Patients whose age is less than 18 years old. 2. Patients who were admitted for less than 24 hours for patient on parenteral anticoagulants and less than 48 hours for patient on warfarin. 3. Patients already admitted for bleeding or thrombosis. 4. Malignancy patients.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent of medication errors change | one year and half | Detect the medication error according to (National Coordinating Council for Medication Errors Reporting and Prevention NCC MERP) Index for Categorizing Medication Errors using NCC MERP Index for Categorizing Medication Errors Algorithm. |
| percent of adverse drug events change | one year and half | Detect bleeding and thrombotic-related adverse drug events |
| Percent of evidence-based guidelines compliance improvement | one year and half | Detect health care providers' adherence to evidence-based guidelines for anticoagulation therapy. |
Countries
Egypt
Outcome results
None listed